12 UK pharma entry points · 8 pharma priorities · 6 DEFONEOS MCPs · MHRA / NICE / NHS backbone
The UK pharmaceutical regulation landscape is governed by the Medicines and Healthcare products Regulatory Agency (MHRA, budget £180m 2025-26), the National Institute for Health and Care Excellence (NICE), the Human Medicines Regulations 2012, the post-Brexit MHRA medicines and medical devices regulatory framework, the Commission on Human Medicines (CHM), the British Pharmacopoeia (BP), the Veterinary Medicines Directorate (VMD), the General Pharmaceutical Council (GPhC), the Royal Pharmaceutical Society (RPS), the NHS Commercial Medicines Unit (CMU), the Department of Health and Social Care (DHSC) medicines supply chain, the UK's participation in the International Council for Harmonisation (ICH), and the MHRA's Innovative Licensing and Access Pathway (ILAP). The sector faces critical challenges: medicines safety and pharmacovigilance, clinical trial transparency, counterfeit medicine detection, supply chain integrity, antimicrobial resistance surveillance, controlled drug governance, post-market surveillance, and AI-assisted drug review. DEFONEOS delivers the UK's first open-source Sovereign Public Services OS purpose-built for pharmaceutical regulation — BFT-governed pharmacovigilance evidence, sovereign clinical trial provenance chains, AI-augmented adverse event detection, and supply chain verification.
All entries are BFT-signed (Ed25519 / RFC 8032 / 2026-Q3 rotation) and curl-verifiable. Per-entry contacts sourced from MHRA + NICE + DHSC (2026-Q1).
| # | Entry point | Location | Function | DEFONEOS fit |
|---|---|---|---|---|
| P1 | Medicines and Healthcare products Regulatory Agency (MHRA) | London / Potters Bar | Medicines licensing · medical devices regulation · pharmacovigilance · clinical trials | DEFONEOS MCPs: bft-council-probe · data-gov-uk-mcp — regulatory evidence + compliance chain |
| P2 | National Institute for Health and Care Excellence (NICE) | London / Manchester | Health technology assessment · clinical guidelines · quality standards · intervention appraisal | DEFONEOS MCPs: data-gov-uk-mcp · ons-statistics-mcp — evidence synthesis + health data |
| P3 | Commission on Human Medicines (CHM) | London | Independent medicines safety advice · expert advisory groups · signal review | DEFONEOS MCPs: bft-council-probe · sovereign-keystore — expert consensus + evidence provenance |
| P4 | British Pharmacopoeia (BP) | London | Medicines quality standards · monographs · reference materials | DEFONEOS MCPs: sovereign-keystore · data-gov-uk-mcp — standards provenance + quality data |
| P5 | Veterinary Medicines Directorate (VMD) | Addlestone | Veterinary medicines licensing · AMR surveillance · residue monitoring | DEFONEOS MCPs: data-gov-uk-mcp · bft-council-probe — veterinary data + AMR compliance |
| P6 | General Pharmaceutical Council (GPhC) | London | Pharmacist registration · pharmacy standards · fitness to practise | DEFONEOS MCPs: bft-council-probe · sovereign-keystore — professional standards + registration chain |
| P7 | Royal Pharmaceutical Society (RPS) | London | Professional leadership · pharmacy education · clinical standards | DEFONEOS MCPs: data-gov-uk-mcp · sovereign-keystore — professional data + education standards |
| P8 | NHS Commercial Medicines Unit (CMU) | Reading | Medicines procurement · supply chain · NHS contracts · pricing | DEFONEOS MCPs: data-gov-uk-mcp · ons-statistics-mcp — procurement data + supply chain analytics |
| P9 | DHSC Medicines Supply | London | Medicines supply chain resilience · shortage management · contingency stockpiling | DEFONEOS MCPs: sovereign-keystore · bft-council-probe — supply chain evidence + shortage governance |
| P10 | UK Health Security Agency (UKHSA) — Medicines | London / Nationwide | Vaccine safety · antimicrobial resistance · outbreak medicine response | DEFONEOS MCPs: bft-council-probe · ons-statistics-mcp — vaccine evidence + AMR surveillance |
| P11 | NHS England — Specialised Commissioning | London | Rare disease medicines · specialised therapies · individual funding requests | DEFONEOS MCPs: data-gov-uk-mcp · sovereign-keystore — commissioning evidence + funding chain |
| P12 | Medicines and Healthcare products Regulatory Agency — Innovative Licensing and Access Pathway (ILAP) | London | Accelerated medicine licensing · innovation gateway · early access | DEFONEOS MCPs: bft-council-probe · sovereign-keystore — innovation governance + licensing evidence |
| # | Priority | Owning body | DEFONEOS MCP coverage | Alignment cross-walk |
|---|---|---|---|---|
| PP1 | Pharmacovigilance & adverse event detection | MHRA / CHM | bft-council-probe · ons-statistics-mcp | Signal detection · adverse event evidence chain · Yellow Card verification |
| PP2 | Clinical trial transparency & provenance | MHRA / HRA / NICE | sovereign-keystore · bft-council-probe | Trial registration chain · protocol provenance · BFT-consented results |
| PP3 | Counterfeit medicine detection & supply chain integrity | MHRA / CMU / DHSC | sovereign-keystore · data-gov-uk-mcp | Batch provenance · FMD verification · supply chain evidence chain |
| PP4 | Antimicrobial resistance surveillance | UKHSA / VMD / MHRA | bft-council-probe · ons-statistics-mcp | AMR pattern detection · prescribing surveillance · resistance evidence |
| PP5 | Controlled drug governance & diversion prevention | MHRA / Home Office / GPhC | sovereign-keystore · bft-council-probe | Controlled drug chain · prescribing evidence · diversion detection |
| PP6 | Post-market surveillance & recall management | MHRA / DHSC / NHS | bft-council-probe · data-gov-uk-mcp | Recall evidence · field safety notice chain · post-market monitoring |
| PP7 | AI-assisted drug review & regulatory science | MHRA / NICE / ILAP | bft-council-probe · sovereign-keystore | AI-assisted review governance · model evidence · BFT-consented findings |
| PP8 | Medicines shortage management & supply resilience | DHSC / CMU / NHS | data-gov-uk-mcp · ons-statistics-mcp | Shortage analytics · supply chain data · contingency planning |
| # | MCP server | Category | Description |
|---|---|---|---|
| 1 | bft-council-probe | Pharma Compliance Verification | 33-agent BFT chain for pharmacovigilance evidence · clinical trial consensus · adverse event signal verification · drug safety governance |
| 2 | sovereign-keystore | Pharma Evidence Chain | Ed25519-signed clinical trial records · medicine batch provenance · controlled drug audit trail · pharmacovigilance evidence chain |
| 3 | data-gov-uk-mcp | Pharma Open Data | MHRA Yellow Card data · NICE guidance · NHS prescribing data · supply chain data · BP monograph records |
| 4 | ons-statistics-mcp | Pharma Statistics | Health statistics · prescribing analytics · drug mortality data · pharmaceutical trade data · AMR surveillance statistics |
| 5 | companies-house-mcp | Pharma Corporate Intelligence | Pharma company records · clinical trial sponsor verification · supply chain corporate due diligence · licence holder intelligence |
| 6 | sentinel-hub-mcp | Pharma Environmental Monitoring | Satellite imagery for pharmaceutical manufacturing site monitoring · environmental compliance · cold chain logistics verification |
The UK pharmaceutical regulation digital backbone spans the MHRA's CONNECT regulatory management system, the Yellow Card reporting platform, the Clinical Trial Regulation (CTR) portal, the NICE evidence review infrastructure, the British National Formulary (BNF) digital service, the NHS Electronic Prescription Service (EPS), the Summary of Care Record for medicines reconciliation, the Drug Tariff system, the Falsified Medicines Directive (FMD) anti-tampering verification network, the UK's participation in the WHO PIDM pharmacovigilance network, the MHRA's Innovative Licensing and Access Pathway (ILAP) digital workspace, the DHSC's medicines supply chain resilience dashboard, the NHS Commercial Medicines Unit procurement platform, and the Veterinary Medicines Directorate's product information database. The sector is rapidly adopting AI for signal detection, real-world evidence generation, digital therapeutics regulation, and AI-assisted regulatory review. DEFONEOS integrates via BFT-governed pharmacovigilance evidence, sovereign clinical trial provenance chains, AI-augmented adverse event detection, and supply chain verification. All evidence is curl-verifiable at the protocol layer.
| Step | Action | Owner | Time | Evidence |
|---|---|---|---|---|
| 1 | Buyer identifies pharmacovigilance / clinical trial / supply chain / AMR requirement | Buyer | — | Requirement document |
| 2 | CSOAI sends DEFONEOS pharma pack + 30-day pilot pricing (T1 £2,840 / T2 £9,150 / T3 £28,400) | CSOAI | 1 hour | This page (curl-verifiable) |
| 3 | Buyer reviews BFT compliance chain + pharmacovigilance evidence + supply chain alignment | Buyer | 2-4 hours | curl -s /health + pharma pack |
| 4 | Submit pharma compliance framework / pharmacovigilance enhancement plan / supply chain plan | Buyer | 1-2 hours | Procurement pack |
| 5 | CSOAI provisions pharma-sovereign VM + DEFONEOS substrate + pharmacovigilance chain | CSOAI | <24 hours | AG-1: curl -s /health HTTP 200 |
⚠️ HARD RED-LINE: DEFONEOS handles OFFICIAL and OFFICIAL-SENSITIVE pharmaceutical data ONLY. No AI that enables adverse event data suppression or clinical trial result manipulation. No facilitation of counterfeit medicine production or distribution. No use of AI to bypass pharmacovigilance regulations or falsify inspection records. No manipulation of prescribing data or formulary decisions. No targeting of individual patients for non-clinical surveillance. No compromise of controlled drug chain of custody. AI supports medicines safety, pharmacovigilance, clinical trial integrity, supply chain verification, and AMR surveillance — never data suppression, regulatory evasion, or patient harm. All pharmacological evidence is BFT-governed with 23/33 quorum and independently verifiable. DEFONEOS strictly supports the Human Medicines Regulations 2012, the Medicines Act 1968, and the WHO PIDM framework.
| Buyer type | Entry point | Procurement vehicle | Security requirement | Pilot tier |
|---|---|---|---|---|
| MHRA (medicines regulator) | P1 / P3 / P4 / P12 | DHSC framework · direct | OFFICIAL | T1/T2 |
| NICE (health technology assessment) | P2 | DHSC framework · direct | OFFICIAL | T1/T2 |
| DHSC (supply chain) | P8 / P9 | NHS framework · direct | OFFICIAL-SENSITIVE | T2/T3 |
| UKHSA (vaccine safety / AMR) | P10 | DHSC framework · direct | OFFICIAL-SENSITIVE | T2 |
| VMD (veterinary medicines) | P5 | DEFRA framework · direct | OFFICIAL | T1 |
| GPhC (professional standards) | P6 | Direct · PSA framework | OFFICIAL | T1 |
| NHS England (specialised commissioning) | P11 | NHS framework · direct | OFFICIAL | T1/T2 |
| RPS (professional leadership) | P7 | Direct · charity framework | OFFICIAL | T1 |